Phase 1 study of the safety and acceptability of 3% w/w SPL7013 gel (VivaGel) applied vaginally in sexually active young women

Trial Profile

Phase 1 study of the safety and acceptability of 3% w/w SPL7013 gel (VivaGel) applied vaginally in sexually active young women

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs Astodrimer (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Sponsors Starpharma
  • Most Recent Events

    • 09 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Planned number of patients changed from 40 to 61 as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Planned end date changed from 1 Mar 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top